| Title: | Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy : an analysis of real-world clinical practice data in Japan |
| Authors: | Matsumoto, Ryuji Browse this author |
| Abe, Takashige Browse this author →KAKEN DB |
| Ishizaki, Junji Browse this author |
| Kikuchi, Hiroshi Browse this author |
| Harabayashi, Toru Browse this author |
| Minami, Keita Browse this author |
| Sazawa, Ataru Browse this author →KAKEN DB |
| Mochizuki, Tango Browse this author |
| Akino, Tomoshige Browse this author |
| Murakumo, Masashi Browse this author |
| Osawa, Takahiro Browse this author |
| Maruyama, Satoru Browse this author →KAKEN DB |
| Murai, Sachiyo Browse this author |
| Shinohara, Nobuo Browse this author →KAKEN DB |
| Keywords: | urothelial carcinoma |
| chemotherapy |
| second-line |
| metastatic |
| Issue Date: | Aug-2018 |
| Publisher: | Oxford University Press |
| Journal Title: | Japanese journal of clinical oncology |
| Volume: | 48 |
| Issue: | 8 |
| Start Page: | 771 |
| End Page: | 776 |
| Publisher DOI: | 10.1093/jjco/hyy094 |
| Abstract: | Objectives: The objective of the present study was to investigate the survival outcome and prognostic factors of metastatic urothelial carcinoma patients treated with second-line systemic chemotherapy in real-world clinical practice. Methods: Overall, 114 patients with metastatic urothelial carcinoma undergoing second-line systemic chemotherapy were included in this retrospective analysis. The dominant second-line chemotherapy was a paclitaxel-based combination regimen (60%, 68/114). We assessed the progression-free survival and overall survival times using the Kaplan-Meier method. The Cox proportional hazards model was applied to identify the factors affecting overall survival. Results: The median progression-free survival and overall survival times were 4 and 9 months, respectively. In the multivariate analysis, an Eastern Cooperative Oncology Group performance status score greater than 0 at presentation, C-reactive protein level ≧1 mg/dl and poor response to prior chemotherapy were adverse prognostic indicators. Patients with 0, 1, 2 and 3 of those risk factors had a median overall survival of 17, 12, 7 and 3 months, respectively. Conclusions: The Eastern Cooperative Oncology Group performance status at presentation, C-reactive protein level and response to prior chemotherapy were prognostic factors for metastatic urothelial carcinoma patients undergoing second-line chemotherapy. In the future, this information might help guide the choice of salvage treatment, such as second-line chemotherapy or immune checkpoint inhibitors, after the failure of first-line chemotherapy. |
| Rights: | http://creativecommons.org/licenses/by-nc/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/72012 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
